Bristol to pay SystImmune up to $8.4 billion in cancer-drug deal
Bristol Myers Squibb Co. will pay SystImmune Inc. up to $8.4 billion for rights to co-develop and sell an experimental drug for lung and breast cancers, the latest in a string of large deals for a potent new class of oncology treatments. The agreement includes an $800 million upfront payment to SystImmune and as much […]